{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Early Breast Cancer Trialists' Collaborative Group (EBCTCG)"],"funding":["NCATS NIH HHS","Cancer Research UK","Medical Research Council","National Institute for Health Research (NIHR)","NCI NIH HHS"],"pagination":["1440-1452"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6451189"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["393(10179)"],"pubmed_abstract":["<h4>Background</h4>Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, might enhance efficacy.<h4>Methods</h4>To clarify the relative benefits and risks of dose-intense and standard-schedule chemotherapy in early breast cancer, we did an individual patient-level meta-analysis of trials comparing 2-weekly versus standard 3-weekly schedules, and of trials comparing sequential versus concurrent administration of anthracycline and taxane chemotherapy. The primary outcomes were recurrence and breast cancer mortality. Standard intention-to-treat log-rank analyses, stratified by age, nodal status, and trial, yielded dose-intense versus standa"],"journal":["Lancet (London, England)"],"pubmed_title":["Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials."],"pmcid":["PMC6451189"],"funding_grant_id":["MC_U137686850","UL1 TR000371","27691","NF-SI-0512-10122","P30 CA008748","21133","25351","MC_U137686858","NF-SI-0616-10107","MC_UU_12026/1"],"pubmed_authors":["Mackey J","Cufer T","Mavroudis D","Gelmon K","Wood W","Harbeck N","Kilburn L","Fountzilas G","Dolci S","Yarnold J","Jagsi R","Pierce L","Cirrincione C","Coleman R","James S","Jackisch C","Brain E","Zambetti M","Taylor C","Untch M","Rutgers E","Martin M","Burrett J","Cuzick J","Bruzzi P","Ingle J","Norton L","Fisher B","Bartelink H","Poortmans P","Giuliano M","Costantino J","Forbes J","Julien JP","Davies L","Levine M","Bamia C","Tutt A","Davies C","Ewertz M","Viale G","Pastorino S","MacKinnon E","Bartlett J","Geyer C","Larsimont D","Bass G","Correa C","Piedbois P","Gettins L","Shao YF","Shepherd L","Coates A","Gerber B","Dodwell D","Muss H","Raina V","Blohmer JU","Gray R","Di Leo A","Paik S","Mannu G","Chia S","Peer P","A'Hern R","Mobus V","Costa S","Bradley R","Nogaret JM","Piccart M","Ohashi Y","Sadoon M","Carrasco E","Steger G","Regan M","Barlow W","Godwin J","De Laurentiis M","Arriagada R","Foukakis T","Bergsten Nordstrom E","Mukai H","Clarke M","Tulusan AH","Pater J","Bergh J","Shan Y","Del Mastro L","Hill C","Mamounas EP","Loibl S","Bogaerts J","Wang X","Wang Y","Parulekar W","Goodwin P","Wang Z","Braybrooke J","Evans V","Dignam J","Rea D","Broadwater G","Tu D","Ellis P","Carey L","Berry D","van de Velde C","Chen B","Redmond C","Pritchard KI","Segui MA","von Minckwitz G","Duane F","Vliek S","De Placido S","Gnant M","Rakovitch E","Bighin C","Sertoli MR","Ravdin P","Davidson N","Linn S","Gelber R","Koliou GA","Wolmark N","Liu H","Philippson C","Morden J","Read S","Boddington C","Anderson S","Cameron D","Albain K","Peto R","Swain S","Hayes D","Zhao DB","Wickerham DL","Goldhirsch A","Liu Z","Morris P","Bramwell VH","Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","Francis P","Xu B","Weiss R","Boccardo F","Sparano J","Tjan-Heijnen V","Goss P","Venturini M","Pronzato P","McGale P","Bliss J","Pan H","Fasching P","Bijker N","Dowsett M","Slamon D","Nekljudova V","Hills R","Wilcken N","McHugh T","Cardoso F","Robertson J","Janni W","Whelan T"],"additional_accession":[]},"is_claimable":false,"name":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.","description":"<h4>Background</h4>Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, might enhance efficacy.<h4>Methods</h4>To clarify the relative benefits and risks of dose-intense and standard-schedule chemotherapy in early breast cancer, we did an individual patient-level meta-analysis of trials comparing 2-weekly versus standard 3-weekly schedules, and of trials comparing sequential versus concurrent administration of anthracycline and taxane chemotherapy. The primary outcomes were recurrence and breast cancer mortality. Standard intention-to-treat log-rank analyses, stratified by age, nodal status, and trial, yielded dose-intense versus standa","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Apr","modification":"2026-05-06T21:34:17.837Z","creation":"2019-06-06T21:07:08Z"},"accession":"S-EPMC6451189","cross_references":{"pubmed":["30739743"],"doi":["10.1016/S0140-6736(18)33137-4"]}}